Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.

Nagano Y, Yokouchi H, Saito R, Honjo O, Sumi T, Kaburagi T, Ito K, Ikezawa Y, Yokoo K, Kikuchi H, Kudo S, Yamazoe M, Shigaki R, Tagami K, Tenma T, Ishikawa T, Takahashi M, Sasaki T, Asahina H, Hinotsu S, Chiba H, Oizumi S

Open source

DOI: 10.1111/cas.70400
Published: 2026 Aug
Container: Cancer science
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/cas.70400,
  title = {Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.},
  author = {Nagano Y and Yokouchi H and Saito R and Honjo O and Sumi T and Kaburagi T and Ito K and Ikezawa Y and Yokoo K and Kikuchi H and Kudo S and Yamazoe M and Shigaki R and Tagami K and Tenma T and Ishikawa T and Takahashi M and Sasaki T and Asahina H and Hinotsu S and Chiba H and Oizumi S},
  year = {2026},
  journal = {Cancer science},
  doi = {10.1111/cas.70400},
  url = {https://doi.org/10.1111/cas.70400}
}

RIS

TY  - JOUR
TI  - Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.
AU  - Nagano Y
AU  - Yokouchi H
AU  - Saito R
AU  - Honjo O
AU  - Sumi T
AU  - Kaburagi T
AU  - Ito K
AU  - Ikezawa Y
AU  - Yokoo K
AU  - Kikuchi H
AU  - Kudo S
AU  - Yamazoe M
AU  - Shigaki R
AU  - Tagami K
AU  - Tenma T
AU  - Ishikawa T
AU  - Takahashi M
AU  - Sasaki T
AU  - Asahina H
AU  - Hinotsu S
AU  - Chiba H
AU  - Oizumi S
PY  - 2026
JO  - Cancer science
DO  - 10.1111/cas.70400
UR  - https://doi.org/10.1111/cas.70400
ER  -

APA

Y, N., H, Y., R, S., O, H., T, S., T, K., K, I., Y, I., K, Y., H, K., S, K., M, Y., R, S., K, T., T, T., T, I., M, T., T, S., H, A., S, H., H, C., & S, O. (2026). Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.. Cancer science. https://doi.org/10.1111/cas.70400

Source records

pubmed · retrieved 2026-09-25T07:57:16.351Z